[go: up one dir, main page]

JPS6485072A - Recombinant vaccinia virus - Google Patents

Recombinant vaccinia virus

Info

Publication number
JPS6485072A
JPS6485072A JP62240514A JP24051487A JPS6485072A JP S6485072 A JPS6485072 A JP S6485072A JP 62240514 A JP62240514 A JP 62240514A JP 24051487 A JP24051487 A JP 24051487A JP S6485072 A JPS6485072 A JP S6485072A
Authority
JP
Japan
Prior art keywords
vaccinia virus
originated
recombinant
recombinant vector
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62240514A
Other languages
Japanese (ja)
Inventor
Asato Kojima
Takeshi Kurata
Atsushi Yasuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zeon Corp
National Institutes of Health NIH
Original Assignee
Nippon Zeon Co Ltd
National Institutes of Health NIH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zeon Co Ltd, National Institutes of Health NIH filed Critical Nippon Zeon Co Ltd
Priority to JP62240514A priority Critical patent/JPS6485072A/en
Publication of JPS6485072A publication Critical patent/JPS6485072A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PURPOSE:To produce tat protein in high expressivity, by using a cDNA coding tat protein originated from human immunodeficiency syndrome virus HIV and synthesizing a recombinant vaccinia virus by integrating said cDNA in a specific region. CONSTITUTION:The 1st recombinant vector is prepared by integrating a DNA region nonessential to the proliferation of vaccinia virus. A region coding tat protein originated from HIV is inserted to the downstream of the promoter of the 1st recombinant vector to obtain the 2nd recombinant vector. The 2nd recombinant vector is introduced into a cultural cell of an animal infected with vaccinia virus to induce a homologous recombination between the vector DNA and the virus genom DNA to construct the objective recombinant vaccinia virus. The cultured animal cell is e.g. TK-143 originated from human osteosarcoma and FL originated from human amnion.
JP62240514A 1987-09-25 1987-09-25 Recombinant vaccinia virus Pending JPS6485072A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP62240514A JPS6485072A (en) 1987-09-25 1987-09-25 Recombinant vaccinia virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62240514A JPS6485072A (en) 1987-09-25 1987-09-25 Recombinant vaccinia virus

Publications (1)

Publication Number Publication Date
JPS6485072A true JPS6485072A (en) 1989-03-30

Family

ID=17060653

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62240514A Pending JPS6485072A (en) 1987-09-25 1987-09-25 Recombinant vaccinia virus

Country Status (1)

Country Link
JP (1) JPS6485072A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012137071A2 (en) 2011-04-06 2012-10-11 Biovaxim Limited Pharmaceutical compositions for preventing and/or treating an hiv disease in humans

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012137071A2 (en) 2011-04-06 2012-10-11 Biovaxim Limited Pharmaceutical compositions for preventing and/or treating an hiv disease in humans

Similar Documents

Publication Publication Date Title
Kannagi et al. Target epitope in the Tax protein of human T-cell leukemia virus type I recognized by class I major histocompatibility complex-restricted cytotoxic T cells
DE69435316D1 (en) PROCESS FOR THE PREPARATION OF HIGH VIRUS TITLES AND THE HIGHLY EFFICIENT TRANSDUCTION OF MICE CELLS BY RETROVIRUSES
ATE120234T1 (en) HIV-3 RETROVIRUS AND ITS USE.
ES2002490A6 (en) Vaccines and immunoassays for acquired immune deficiency syndrome
EP0278940A3 (en) Hepatitis b virus surface antigens and hybrid antigens containing them
RU94042722A (en) Chimeric protein, gene, cell, vector, method of chimeric protein preparing, vaccine
MY117686A (en) Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof
DK1224314T3 (en) Lentiviral triplex DNA, as well as vectors and recombinant cells, contain lentiviral triplex DNA
NO921969L (en) NON-REPLICATING RECOMBINANT MANUFACTURED RETROVIRUS PARTICLES USED AS ANTIVIRAL AGENTS AND IMMUNOGENS
JPS6479124A (en) Factor viii analogue, manufacture and medicine
CA2104396A1 (en) Viral particles having altered host range
WO1995006743A3 (en) Methods and compositions for the large scale production of recombinant adeno-associated virus
IL86650A0 (en) Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
JPS6446651A (en) Antibody for retrovirus polypeptide
EA200000528A1 (en) METHOD FOR OBTAINING VACCINES TO PREVENT PATHOGENIC EFFECTS ASSOCIATED WITH RETROVIRAL INFECTION
RU2003128991A (en) RECOMBINANT POXVIRUS CODING HIMERA IMMUNODEFICIENCY VIRUS CHEMICAL PROTEINS
CA2169603A1 (en) Retrovirus from the hiv group and its use
JPS6485098A (en) Glycoprotein and production thereof
WO1994013812A3 (en) Novel entomopoxvirus genes, proteins and methods of use thereof
Hejdeman et al. DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy
JPS6485072A (en) Recombinant vaccinia virus
ES2061850T3 (en) RECOMBINANT VIRUSES OF MAREK'S DISEASE, ITS PREPARATION PROCEDURE AND VACCINE.
EP0327180A3 (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
IL75553A (en) Dna sequence coding for a cholinesterase-like peptide, peptides produced by cells containing said dna and antibodies thereto
MY104530A (en) Nonreplicating recombinant-made retroviral particles useful as anti-viral agents and as immunogens for pro- phylaxis and therapy against human retroviruses.